Drug profile · INN
regadenoson
RAPISCAN
regadenoson (RAPISCAN) is a adenosine a2a receptor agonist. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — regadenoson
- US status
- approved
- Class
- Cardiovascular system (C01)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
regadenoson (RAPISCAN) is a adenosine a2a receptor agonist. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Adenosine A2a receptor agonist
Primary target: Adenosine receptor A2a
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is regadenoson?
regadenoson (RAPISCAN) is a adenosine a2a receptor agonist. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for regadenoson?
RAPISCAN is a marketed brand name for regadenoson. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of regadenoson?
regadenoson has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.